14 research outputs found
Analysis of genetic heterogeneity in the HCAR adenovirus-binding Ig1 domain in a Caucasian Flemish population
BACKGROUND: Polymorphisms in the gene that encodes the human cellular receptor for group B coxsackieviruses and adenoviruses (HCAR) could be responsible for differences in susceptibility to infections with these pathogens. Moreover, adenovirus subgroup C-mediated gene therapy could be influenced by mutations in the coding exons for the aminoterminal immunoglobulin-like 1 (Ig1) domain, which is the essential component for adenovirus fiber knob binding. RESULTS: Using two primersets in the adjacent intron sequences, HCAR exons 2 and 3, which comprise the full-length Ig1 domain, were amplified by polymerase chain reactions in 108 unselected and unrelated healthy Belgian volunteers. After nucleotide sequencing, no polymorphisms could be demonstrated in the adenovirus-binding Ig1 exons 2 and 3 of the HCAR gene. CONCLUSIONS: The adenovirus-binding Ig1 domain seems to be a highly conserved region in the Caucasian population which is a reassuring finding regarding adenovector-based gene therapy
Interleukin-1 receptor antagonist VNTR-polymorphism in Crohn's disease and ulcerative colitis
CC chemokine receptor 5 (CCR-5) and serological markers ASCA and pANCA in inflammatory bowel disease (IBD)
Chemokine receptor CCR5 Ξ32 gene polymorphism in Crohn's disease and ulcerative colitis
Analysis of genetic heterogeneity in the HCAR adenovirus-binding Ig1 domain in a Caucasian Flemish population
Pulsotypes and STs of multi drug resistant and/or ESBL producing isolates.
<p>ESBL singletons: ESBL strains with a pulsotype of which no similar type has been demonstrated among the other typed isolates.</p><p>ST β=β sequence type, CC β=β clonal complex, n β=β amount.</p
Antimicrobial resistance among (%) <i>E. coli</i> isolates.
<p>NL β=β the Netherlands, B β=β Belgium and G β=β Germany, - β=β not significant.</p
Antibiotic resistance and suitability of antibiotics for empiric treatment.
<p>Antibiotic resistance for the different antibiotics among the three groups of isolates compared with a 10% resistance cutoff to decide whether an antibiotic agent is suitable for empiric treatment. AMC β=β amoxicillin-clavulanic acid, TZP β=β piperacillin-tazobactam, CXM β=β cefuroxime, CAZ β=β ceftazidime, FIX β=β cefixime, TIB β=β ceftibuten, CIP β=β ciprofloxacin, NIT β=β nitrofurantoin, SXT β=β trimethoprim-sulfamethoxazole and GEN β=β gentamicin.</p